PharmaShots | Incisive News in 3 Shots

Subscribe Now

UroGen Pharma

UroGen Pharma Reports Long-Term Data from OLYMPUS Trial of Jelmyto for Upper Tract Urothelial Cancer

UroGen Pharma Reports Long-Term Data from OLYMPUS Trial of Jelmyto for Upper Tract Urothelial Cancer

November 29, 2024

UroGen Pharma Reports Real-World Analysis of Jelmyto for Upper Tract Urothelial Carcinoma

UroGen Pharma Reports Real-World Analysis of Jelmyto for Upper Tract Urothelial Carcinoma

May 6, 2024

UroGen Pharma Reports P-III Trial (ATLAS) Results of UGN-102 for Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer

UroGen Pharma Reports P-III Trial (ATLAS) Results of UGN-102 for Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer

August 9, 2023

UroGen Pharma Reports P-III Trials (ATLAS) and (ENVISION) Results of UGN-102 as First Non-Surgical Therapy for Non-Muscle Invasive Bladder Cancer

UroGen Pharma Reports P-III Trials (ATLAS) and (ENVISION) Results of UGN-102 as First Non-Surgical Therapy for Non-Muscle Invasive...

July 29, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us